Capula Management Ltd

Q4 2021 13F-HR Detailed Holdings

Location
Grand Cayman, E9
Holdings as of
12/31/2021
Date filed
2/14/2022
Form type
13F-HR
Num holdings
187
Total value ($000)
$4,708,466
Net value change ($000)
-3,406,532 (-42.0%)
New positions
10
Sold out positions
469
Turnover %
69.1%
Sector allocation + QoQ delta (equities-only)

Holdings broken out by other managers reported in the original SEC filing. View aggregated holdings

You are on the SEC detailed breakdown page. Rows are shown as reported in the filing (including other manager, discretion, and voting authority fields), and are not merged like the standard holdings view. Switch to aggregated holdings.

Snapshot: Change Analysis

Compared to Q3 2021
Methodology: sector metrics are equities-only; instrument mix chart is ex-options; options exposure is shown separately. Why this matters.
Top Adds (Value $000, Stocks/ETFs)
SPY 702,366 214.9%
QQQ 206,724 NEW
IWM 26,480 NEW
FXI 20,233 141.7%
XLF 6,526 NEW
ASHR 5,082 NEW
JD 4,905 NEW
XLI 4,029 NEW
PLUG 2,487 NEW
PINS 2,200 NEW
Top Reduces (Value $000, Stocks/ETFs)
AAPL -32,186 -81.0%
MSFT -26,580 -76.5%
META -24,510 -86.9%
PYPL -21,743 -100.0%
ADBE -21,606 -100.0%
AMZN -20,106 -63.3%
BABA -19,032 -100.0%
QCOM -12,444 -100.0%
VRSN -11,293 -100.0%
DIS -10,623 -100.0%
Instrument mix + QoQ Δ (ex-options)
Derivatives reported exposure ($000): 3,293,900 (70.0% of total reported value)
How this table is calculated: SEC VALUE ($000) is used as reported. For derivatives (PUT/CALL/WARRANT/RIGHT), SEC value represents reported underlying exposure, not premium cash paid/received. Column % is bucket-based: non-options share is calculated inside non-option total, options share is calculated inside options total. Details.
Filter:
Instrument:
Issuer Name Ticker Sector Industry Class History Value ($000) % Shares Shares Δ Shares Δ% Value Δ ($000) Value Δ% Principal Option Type Discretion Other Manager Sole Shared None

Other Managers

Num Name File Number
1 Capula Investment US LP 028-17204
2 Capula Investment Management LLP 028-17757